Abbott Labs entering glucose monitoring market with $876 mil. MediSense purchase.
This article was originally published in The Tan Sheet
Executive Summary
ABBOTT ACQUIRING GLUCOSE MONITOR SYSTEMS MAKER MEDISENSE for $876 mil., the firm announced March 29. The definitive agreement, expected to be completed within the next five weeks, would give Abbott entry to the blood glucose monitor market with Waltham, Mass.-based MediSense's line of biosensor-based blood glucose systems, enabling patients with diabetes to test themselves.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning